First-in-human trial of ISIS-FXIRx, an inhibitor of Factor XI production, thought to prevent blood clot formation.

Trial Profile

First-in-human trial of ISIS-FXIRx, an inhibitor of Factor XI production, thought to prevent blood clot formation.

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Dec 2011

At a glance

  • Drugs IONIS FXIRx (Primary)
  • Indications Thromboembolism
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Dec 2011 Results presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology.
    • 12 Dec 2011 Status changed from recruiting to completed, according to an Isis Pharmaceuticals media release.
    • 02 Feb 2011 This trial have been initiated according to an Isis Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top